Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice
- 1 July 2015
- journal article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 41 (3) , 704-715
Abstract
Current antipsychotic drugs (APDs) show efficacy with positive symptoms, but are limited in treating negative or cognitive features of schizophrenia. Whereas all currently FDA-approved medications target primarily the dopamine D2 receptor (D2R) to inhibit G(i/o)-mediated adenylyl cyclase, a recent study has shown that many APDs affect not only G(i/o)- but they can also influence β-arrestin- (βArr)-mediated signaling. The ability of ligands to differentially affect signaling through these pathways is termed functional selectivity. We have developed ligands that are devoid of D2R-mediated G(i/o) protein signaling, but are simultaneously partial agonists for D2R/βArr interactions. The purpose of this study was to test the effectiveness of UNC9975 or UNC9994 on schizophrenia-like behaviors in phencyclidine-treated or NR1-knockdown hypoglutamatergic mice. We have found the UNC compounds reduce hyperlocomotion in the open field, restore PPI, improve novel object recognition memory, partially normalize social behavior, decrease conditioned avoidance responding, and elicit a much lower level of catalepsy than haloperidol. These preclinical results suggest that exploitation of functional selectivity may provide unique opportunities to develop drugs with fewer side effects, greater therapeutic selectivity, and enhanced efficacy for treating schizophrenia and related conditions than medications that are currently available.Keywords
This publication has 53 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Discovery of β-Arrestin–Biased Dopamine D2Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic EfficacyProceedings of the National Academy of Sciences, 2011
- Synaptic dysfunction and abnormal behaviors in mice lacking major isoforms of Shank3Human Molecular Genetics, 2011
- Genetic Models of Sensorimotor Gating: Relevance to Neuropsychiatric Disorders2011
- Reduced Cortical BDNF Expression and Aberrant Memory inCarfKnock-Out MiceJournal of Neuroscience, 2010
- Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophreniaGenes, Brain and Behavior, 2009
- The molecular and cellular biology of enhanced cognitionNature Reviews Neuroscience, 2009
- Antagonism of dopamine D2 receptor/β-arrestin 2 interaction is a common property of clinically effective antipsychoticsProceedings of the National Academy of Sciences, 2008
- Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunctionPharmacology Biochemistry and Behavior, 2006
- The Functional Significance of Social Cognition in Schizophrenia: A ReviewSchizophrenia Bulletin, 2006